Testing firm Genialis has announced the commercial availability of its krasID test, which it calls: “the first biomarker algorithm that predicts patient response and clinical benefit to KRAS inhibitors (KRASi) across tissue histology and mutation type.”  Genialis’s krasID was developed to help guide drug development from early preclinical phases, to…

Researchers from the University of Dundee’s Centre for Targeted Protein Degradation (CeTPD) and collaborators from pharma company Boehringer Ingelheim (BI) have developed a promising new small-molecule drug that has shown efficacy against 13 of the 17 most common KRAS mutant-driven cancers. Details of this new research are published in the…

UNC Lineberger Comprehensive Cancer Center researchers and colleagues, via two separate articles “Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers,” and “Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer,” published today in Science, say they have developed the most comprehensive molecular portrait of the oncogene KRAS and how its activities…

Colorectal and pancreatic cancers—the second and third leading causes of cancer death, respectively—often have mutations in the KRAS protein. Now, a new vaccine that targets KRAS has shown encouraging early results as a potential off-the-shelf treatment for patients with pancreatic cancer or colorectal cancer, according to a study co-led by…

An experimental cancer vaccine developed by Elicio Therapeutics to target tumors with KRAS mutations has achieved good results in a Phase I trial in patients with residual pancreatic and colorectal cancer following earlier treatment. As reported in Nature Medicine, the majority of patients in the study (84%) had a T…

Bristol Myers Squibb (BMS) has signed a $4.8 billion deal to buy Mirati Therapeutics and its cancer drug KRAZATI, which targets KRAS. In December 2022, KRAZATI (adagrasib) was granted accelerated U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic Non-Small…

KRAS is one of the most common cancer-causing genes in humans. To date, researchers have been unable to design a small molecule to block its active form because it lacks a binding pocket. Now, researchers report in Science how they have created a molecular glue that allows the binding of…

A collaborative study by Spanish researchers at the Cancer Research Center (CSIC-University of Salamanca) and The Experimental Oncology group at CNIO (Centro Nacional de Investigaciones Oncológicas) has found the mechanism of KRAS inhibitor tumor resistance and suggest that it can be overcome by more potent drugs or degraders. The study…

KRAS inhibitors made substantial progress this week as both Mirata (adagrasib for colorectal cancer) and Amgen (sotorasib for pancreatic cancer) shared positive trial results in the New England Journal of Medicine. Mirata also netted an FDA Breakthrough Therapy Designation (BTD) for adagrasib (KRAZATI) in combination with cetuximab in patients with KRASG12C-mutated,…

Researchers from the University of Pennsylvania have discovered that a small molecule KRAS-targeted therapy stopped cancer growth or shrank tumors in animal models of pancreatic cancer. They found that the drug inhibits the activity of the most common KRAS mutation in pancreatic cancer and simultaneously boosts T cells mediated immunity.…

Researchers at the University of Pennsylvania School of Medicine, have shown that a small molecule inhibitor of the cancer-causing gene mutation KRAS successfully shrinks tumors and stops cancer growth in preclinical models for pancreatic cancer. Found in nearly 30 percent of all human tumors, KRAS is one of the most…

HOOKIPA Pharma has announced a strategic collaboration and license agreement with Roche to develop its HB-700 immunotherapy for KRAS-mutated cancers and a second undisclosed drug. This is HOOKIPA’s first oncology licensing collaboration. The company is developing a new class of immunotherapies based on its proprietary replicating arenavirus platform. HOOKIPA will…

The KRAS-inhibitor race came into attention this week when non-small cell lung cancer patients with a KRAS G12C mutation had higher progression-free survival (PFS) and objective response rate (ORR) with Amgen’s KRAS inhibitor Lumakras (sotorasib) compared with docetaxel, according to results from a Phase III trial. The data were presented yesterday…

Scientists have discovered that the KRAS gene mutation, which occurs early in the transformation to cancer, leads to the abundant release of a particular type of non-coding RNA that may be useful in early cancer diagnosis. The research team from UC Santa Cruz examined the effects of mutations in the…

Researchers have successfully used an FDA-approved drug to stop the growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths. The achievement takes advantage of the discovery that cells carrying KRAS gene mutations —which are…